The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1122
January 21, 2002
View Complete Issue         Table of Contents 2019 
Cefditoren (Spectracef) - A New Oral Cephalosporin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cefditoren (Spectracef) - A New Oral Cephalosporin
January 21, 2002 (Issue: 1122)
Cefditoren pivoxil (Spectracef — TAP), a new oral third-generation cephalosporin, has been approved by the FDA for treatment of acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis and uncomplicated skin and soft tissue infections...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cefditoren (Spectracef) - A New Oral Cephalosporin
Article code: 1122a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.